ERBB2 and invasive breast carcinoma: RNA-seq derived mRNA levels for the ATG4 paralogs in patients with invasive breast carcinoma (BRCA) were not found to be dynamic between patient groups that differ in ERBB2/HER2 status, including stratification by PAM50 subtype (n=579), by DNA alteration status (amplifications and/or mutations versus wild type; n=959) or by ERBB2 amplification, mRNA overexpression (OE), and/or protein OE versus median expression (n=410) (Supplementary Figure S1).